Galcanezumab

Category: biologic

Aliases: Emgality, anti-CGRP ligand mAb

Pharmacological Mechanism

Humanised IgG4 mAb binding CGRP ligand with high affinity → blocks CGRP engagement of the canonical trigeminovascular receptor. Only CGRP mAb with an FDA indication for episodic cluster headache. Onset within the first month; well tolerated with minimal systemic side effects.

Half-Life (t½)

SC: 648h

Dosing Guidelines

Target Organ Systems